Stock Report

All about this stock under one free report Last Updated: 07-Sep-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Zydus Lifesciences Key Ratios

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: ZYDUSLIFE | BSE: 532321

₹1,120.00

up-down-arrow ₹-23.00 (-2.01%)

As on 04-Sep-2026 15:57IST

Market cap

info icon

₹1,11,820 Cr

Revenue (TTM)

info icon

₹28,592 Cr

P/E Ratio

info icon

24.8

P/B Ratio

info icon

4.1

Div. Yield

info icon

0.1 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 5.67 21.96 21.11 15.80 13.83
EBIT -1.88 -25.71 -8.99 15.66 15.41
Net Profit -39.59 -35.04 4.14 19.21 14.91
EPS -25.55 -35.42 -1.13 21.60 15.21
Book Value -- -- 13.19 15.90 16.26
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-26Mar-25
EBIT-Margin info 32.3520.6119.3521.3025.72
Net Margin info 29.8216.4814.9217.3719.47
Return on equity info 23.5417.6818.7819.6921.08
Return on Capital info 23.2920.26--21.3926.06
Return on Assets info 13.6211.7010.0311.8114.77
Debt to Equity (x) info ----0.120.430.13

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
--
21.39
26.06
24.90
13.64
Peer Median
--
19.34
21.76
21.89
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

18.78

Higher than Peers by 3.43

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
18.78
19.69
21.08
20.52
11.60
Peer Median
15.35
17.67
17.93
16.42
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

10.03

Lower than Peers by 0.32

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
10.03
11.81
14.77
14.70
7.82
Peer Median
10.35
9.88
12.81
12.32
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

19.35

Higher than Peers by 1.34

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
19.35
21.30
25.72
23.20
16.53
Peer Median
18.01
18.96
18.93
21.05
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

14.92

Higher than Peers by 0.46

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
14.92
17.37
19.47
19.24
11.30
Peer Median
14.45
13.32
14.94
15.51
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
--
12.45
12.11
12.12
8.03
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

21.11

Higher than Peers by 9.16

Year on year growth in net sales

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
21.11
16.81
18.90
13.40
14.08
Peer Median
11.95
12.97
10.90
13.44
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-8.99

Lower than Peers by 30.59

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
-8.99
-3.27
31.82
59.16
15.74
Peer Median
21.60
15.05
15.01
23.50
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

4.14

Lower than Peers by 18.60

Year on year growth in profit after tax

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
4.14
8.92
20.45
91.39
-13.95
Peer Median
22.73
11.89
14.80
30.12
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

-1.13

Lower than Peers by 21.16

Year on year growth in earnings per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
-1.13
11.37
17.26
98.06
-55.80
Peer Median
20.03
12.16
14.27
29.02
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
--
13.19
20.80
13.21
3.04
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

0.12

Higher than Peers by 0.11

Total debt / Net worth

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
0.12
0.43
0.13
0.04
0.07
Peer Median
0.00
0.05
0.06
0.03
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
--
0.16
0.13
0.04
0.06
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

1.27

Lower than Peers by 0.82

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
1.27
1.27
1.89
2.14
1.81
Peer Median
2.08
1.93
1.90
2.23
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

0.91

Lower than Peers by 0.63

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
0.91
0.91
1.45
1.50
1.19
Peer Median
1.54
1.52
1.46
1.59
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

12.77

Lower than Peers by 6.60

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
12.77
16.09
32.55
60.22
20.94
Peer Median
19.38
19.95
24.96
45.29
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

18.94

Lower than Peers by 2.44

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
18.94
19.95
17.58
26.71
25.62
Peer Median
21.38
19.87
21.77
20.10
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.64

Lower than Peers by 0.08

Sales / Average Total Assets

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
0.64
1.21
1.46
1.46
1.32
Peer Median
0.72
0.77
0.76
0.81
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
--
33.55
37.17
46.37
41.75
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
--
33.80
29.51
32.98
38.39
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
--
149.82
150.48
147.51
145.80
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
--
-82.46
-83.79
-68.16
-65.67
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

24.78

Lower than Peers by 10.15

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
24.78
17.39
19.69
26.20
25.37
Peer Median
34.93
34.81
26.81
39.85
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

4.15

Lower than Peers by 1.12

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
4.15
3.23
3.72
5.10
2.84
Peer Median
5.27
5.65
4.65
6.11
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

0.09

Lower than Peers by 0.22

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
0.09
0.11
1.24
0.30
1.22
Peer Median
0.31
0.47
0.61
0.37
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

13.92

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
13.92
10.91
12.15
17.78
12.44
Peer Median
--
29.44
27.02
34.57
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

1,11,820

Higher than Peers by 90,713

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Zydus Lifesciences
1,11,820
87,643
89,101
1,01,128
49,740
Peer Median
21,107
18,631
20,914
25,297
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...